Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?
HCA Healthcare reported Q2 2026 results on July 24. Revenue rose 8.7% to $20.23B and diluted EPS rose 11.6% to $7.62, but payer mix worsened and management cut full-year guidance. 2026 diluted EPS was lowered to $28.70-$30.50 and Adjusted EBITDA to $15.40B-$16.10B. Analysts cut price targets after the update.







